Ricardo C. M.
- Country
- Spain
- Department
- None
Research Overview
- A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
- Phase 3 Multinational Randomized Study of Sasanlimab with Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
- Evaluation of Perioperative Pembrolizumab and Enfortumab Vedotin with Cystectomy Versus Cystectomy Alone in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Data & Insights
Has run more than one trial at 75 of 228 partner sites.
Specializations
Breast Cancer
Clinical research in breast cancer spans HER2-positive breast cancer, HER2-negative breast cancer, hormone receptor-positive disease, and triple-negative breast cancer, with attention to early-stage, locally advanced, metastatic, and high-risk settings.
- Endocrine therapy and CDK4/6 inhibition
- HER2-targeted therapy
- PI3K pathway and BRCA-related treatment strategies
- Neoadjuvant and adjuvant breast cancer treatment
Areas of interest also include recurrence prevention, residual disease, and biomarker-directed approaches in ER-positive and PIK3CA-mutated breast cancer.
Hematologic Malignancies
Research activity includes acute myeloid leukemia, myelodysplastic syndromes, myelofibrosis, multiple myeloma, and lymphoid malignancies such as diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia.
- Relapsed or refractory leukemia
- Myeloid neoplasms
- B-cell lymphoma
- Plasma cell disorders
Therapeutic focus extends to targeted agents, immunotherapy, and treatment options for patients with limited standard choices in aggressive blood cancers.
Genitourinary and Gynecologic Oncology
Clinical trials also address prostate cancer, bladder cancer, urothelial carcinoma, ovarian cancer, and pancreatic adenocarcinoma, covering both advanced and recurrent disease.
- Androgen receptor–directed therapy
- Bladder cancer immunotherapy
- Ovarian cancer maintenance treatment
- CLDN18.2-targeted therapy
Interest in these domains includes metastatic disease control, recurrence delay, and biomarker-selected treatment options across solid tumors.
Melanoma and Lung Cancer
Work in melanoma and non-small-cell lung cancer includes resected, unresectable, and metastatic settings, with emphasis on systemic therapy for high-risk disease.
- Immune checkpoint blockade
- Perioperative treatment
- Adjuvant therapy
- Resectable solid tumors
These studies reflect involvement in treatment strategies aimed at improving disease-free control in surgically managed and advanced thoracic and skin cancers.
Cardiovascular and Immune-Mediated Conditions
Additional research interests include atherosclerotic cardiovascular disease, coronary artery disease, calcific aortic valve stenosis, cardiomyopathy, paroxysmal nocturnal hemoglobinuria, immune thrombocytopenia, and autoinflammatory diseases.
- Lipid-lowering and antithrombotic therapy
- Structural heart disease
- Complement-mediated disorders
- Inflammatory and hematologic immune disorders
These areas show engagement with medical innovation beyond oncology, including preventive cardiovascular care and immune-pathway–driven disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.